These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38688250)

  • 1. Prediction of Clinical Response to Dupilumab in Patients with Severe Asthma Using Fractional Exhaled Nitric Oxide Combined with Pulmonary Function Testing.
    Liu YL; Zhang Y
    Int Arch Allergy Immunol; 2024; 185(9):856-864. PubMed ID: 38688250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baseline FeNO Independently Predicts the Dupilumab Response in Patients With Moderate-to-Severe Asthma.
    Pavord ID; Deniz Y; Corren J; Casale TB; FitzGerald JM; Izuhara K; Daizadeh N; Ortiz B; Johnson RR; Harel S; Djandji M; Goga L; Crikelair N; Rowe PJ; Busse WW
    J Allergy Clin Immunol Pract; 2023 Apr; 11(4):1213-1220.e2. PubMed ID: 36535524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of dupilumab and risk factors for dupilumab-induced hypereosinophilia in severe asthma: a preliminary study from China.
    Li Y; Deng Z; Wen J; Ou C; Cen X; Liao Y; Zhang Q; Xie J
    Ann Med; 2024 Dec; 56(1):2311843. PubMed ID: 38316016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dupilumab Efficacy in Patients with Uncontrolled Moderate-to-Severe Type 2 Asthma Regardless of Perennial Aeroallergen Sensitization.
    Corren J; Jackson DJ; Casale TB; Borish L; Rabe KF; Busse WW; Maspero JF; Jackson DJ; Daizadeh N; Altincatal A; Radwan A; Khodzhayev A; Djandji M; Jacob-Nara JA; Rowe PJ; Deniz Y
    J Asthma Allergy; 2023; 16():249-260. PubMed ID: 36915284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early effectiveness of type-2 severe asthma treatment with dupilumab in a real-life setting; a FeNO-driven choice that leads to winning management.
    Carpagnano GE; Scioscia G; Buonamico E; Lacedonia D; Diaferia F; Capozza E; Lepore G; Resta O; Foschino Barbaro MP
    Multidiscip Respir Med; 2022 Jan; 17(1):797. PubMed ID: 35280851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of dupilumab in patients with uncontrolled, moderate-to-severe asthma with fungal sensitization.
    Corren J; Hanania NA; Busse WW; Sher LD; Altincatal A; Hardin M; Mannent LP; Amin N; Lederer DJ; Soler X; Jacob-Nara JA; Rowe PJ; Deniz Y
    Clin Exp Allergy; 2023 Oct; 53(10):1020-1030. PubMed ID: 37752621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eosinophil Cationic Protein Variation in Patients with Asthma and CRSwNP Treated with Dupilumab.
    Ledda AG; Costanzo G; Sambugaro G; Caruso C; Bullita M; Di Martino ML; Serra P; Firinu D; Del Giacco S
    Life (Basel); 2023 Sep; 13(9):. PubMed ID: 37763288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dupilumab Reduces Exacerbations Independent of Changes in Biomarkers in Moderate-to-Severe Asthma.
    Pavord ID; Casale TB; Corren J; FitzGerald MJ; Deniz Y; Altincatal A; Gall R; Pandit-Abid N; Radwan A; Jacob-Nara JA; Rowe PJ; Busse WW
    J Allergy Clin Immunol Pract; 2024 Jul; 12(7):1763-1772. PubMed ID: 38555079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Use of Exercise Challenge Testing and Fractional Exhaled Nitric Oxide in Diagnosis of Chest Tightness Variant Asthma in Children.
    Feng Y; Zhang S; Shang Y; Chen N
    Int Arch Allergy Immunol; 2022; 183(7):762-769. PubMed ID: 35158359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of Fractional Exhaled Nitric Oxide in Diagnosing Asthmatic Type 2 Chronic Rhinosinusitis With Nasal Polyps.
    Park JA; Cha H; Yang SK; Ryu HT; Kim DW; Hong SN; Yang MS; Kim DW
    Am J Rhinol Allergy; 2023 Sep; 37(5):524-530. PubMed ID: 37160729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world effectiveness and predictors of super-responders to dupilumab in a Chinese uncontrolled asthma cohort.
    Chen X; Luo H; Yan W; Tang K; Huang J; Xie S; Lin Z; Zhang Z; Shi X; Xian M; Wang W; Li J; Chen R
    Allergy Asthma Proc; 2024 Jan; 45(1):e14-e22. PubMed ID: 38151737
    [No Abstract]   [Full Text] [Related]  

  • 12. Relationship between Fractional Exhaled Nitric Oxide Level and Efficacy of Inhaled Corticosteroid in Asthma-COPD Overlap Syndrome Patients with Different Disease Severity.
    Feng JX; Lin Y; Lin J; He SS; Chen MF; Wu XM; Xu YZ
    J Korean Med Sci; 2017 Mar; 32(3):439-447. PubMed ID: 28145647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Correlation Between Fractional Exhaled Nitric Oxide (FeNO), Blood Eosinophil Count, Immunoglobulin E Levels, and Spirometric Values in Patients With Asthma.
    Al Ghobain MO; Alsubaie AS; Aljumah WA; Alrumayh FM; Aldawsari KF; Alqahtani AM; Alotaibi SN
    Cureus; 2023 Feb; 15(2):e35289. PubMed ID: 36968856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Exacerbation History on Dupilumab Efficacy in Children with Uncontrolled Moderate-to-Severe Asthma: LIBERTY ASTHMA VOYAGE Study.
    Guilbert TW; Tolcachier A; Fiocchi AG; Katelaris CH; Phipatanakul W; Begin P; de Mir I; Altincatal A; Gall R; Ledanois O; Radwan A; Jacob-Nara JA; Deniz Y; Rowe PJ
    J Asthma Allergy; 2024; 17():143-159. PubMed ID: 38476213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dupilumab reduced impact of severe exacerbations on lung function in patients with moderate-to-severe type 2 asthma.
    Papi A; Corren J; Castro M; Domingo C; Rogers L; Chapman KR; Jackson DJ; Daizadeh N; Pandit-Abid N; Gall R; Jacob-Nara JA; Rowe PJ; Deniz Y; Ortiz B
    Allergy; 2023 Jan; 78(1):233-243. PubMed ID: 35899469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-life effects of dupilumab in patients with severe type 2 asthma, according to atopic trait and presence of chronic rhinosinusitis with nasal polyps.
    Pelaia C; Benfante A; Busceti MT; Caiaffa MF; Campisi R; Carpagnano GE; Crimi N; D'Amato M; Foschino Barbaro MP; Maglio A; Minenna E; Nolasco S; Paglino G; Papia F; Pelaia G; Portacci A; Ricciardi L; Scichilone N; Scioscia G; Triggiani M; Valenti G; Vatrella A; Crimi C
    Front Immunol; 2023; 14():1121237. PubMed ID: 37063895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low Serum IL-18 Levels May Predict the Effectiveness of Dupilumab in Severe Asthma.
    Watanabe S; Suzukawa M; Tashimo H; Ohshima N; Asari I; Takada K; Imoto S; Nagase T; Ohta K
    Intern Med; 2024 Jan; 63(2):179-187. PubMed ID: 37225484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dupilumab Improves Asthma Control and Lung Function in Patients with Insufficient Outcome During Previous Antibody Therapy.
    Mümmler C; Munker D; Barnikel M; Veit T; Kayser MZ; Welte T; Behr J; Kneidinger N; Suhling H; Milger K
    J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1177-1185.e4. PubMed ID: 32980583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dupilumab is effective in type 2-high asthma patients receiving high-dose inhaled corticosteroids at baseline.
    Bourdin A; Papi AA; Corren J; Virchow JC; Rice MS; Deniz Y; Djandji M; Rowe P; Pavord ID
    Allergy; 2021 Jan; 76(1):269-280. PubMed ID: 33010038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The value of small airway function parameters and fractional exhaled nitric oxide for predicting positive methacholine challenge test in asthmatics of different ages with FEV
    Hou L; Hao H; Huang G; Liu J; Yu L; Zhu L; Shen H; Zhang M
    Clin Transl Allergy; 2021 Mar; 11(1):e12007. PubMed ID: 33900045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.